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Iron is essential for mammalian cellular homeostasis. However, in excess, it promotes free
radical formation and is associated with aging-related progressive deterioration and with
neurodegenerative disorders such as Alzheimer’s disease (AD). There are no mechanisms
to excrete iron, which makes iron homeostasis a very tightly regulated process at the level
of the intestinal absorption. Iron is believed to reach the brain through receptor-mediated
endocytosis of iron-bound transferrin by the brain barriers, the blood-cerebrospinal fluid
(CSF) barrier, formed by the choroid plexus (CP) epithelial cells and the blood-brain barrier
(BBB) formed by the endothelial cells of the brain capillaries. Importantly, the CP epithelial
cells are responsible for producing most of the CSF, the fluid that fills the brain ventricles
and the subarachnoid space. Recently, the finding that the CP epithelial cells display all the
machinery to locally control iron delivery into the CSF may suggest that the general and
progressive senescence of the CP may be at the basis of the impairment of regional iron
metabolism, iron-mediated toxicity, and the increase in inflammation and oxidative stress
that occurs with aging and, particularly, in AD.
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INTRODUCTION
Since iron deregulation is relevant for Alzheimer’s disease (AD),
in this review we focus on the relevance of iron metabolism reg-
ulation, particularly in the central nervous system (CNS). Iron
accumulation occurs in specific brain areas that are affected in
AD patients, such as the hippocampus and the cortex (Crichton
et al., 2011). In these areas, iron and proteins that bind iron
accumulate in the amyloid plaques (Silvestri and Camaschella,
2008; Leskovjan et al., 201 ) and appear to play a role in the
degree of tau phosphorylation (Egana et al., 2003). Furthermore,
molecules that are directly or indirectly involved in the amy-
loidogenic pathway, such as amyloid precursor protein (APP)
(Duce et al., 2010) and paired basic amino acid cleaving enzyme
(PACE/furin) (Silvestri and Camaschella, 2008), have an iron-
related physiological function that depends on the brain iron
levels. Iron access into the brain is modulated by the brain bar-
riers, which have recently been proposed as active modulators of
brain iron homeostasis (Moos et al., 2007; Marques et al., 2009a;
Rouault et al., 2009). Here, we will focus mostly on the choroid
plexus (CP), since several functions (and dysfunctions) of the CP,
both in healthy and pathological conditions, may impact on the
CNS mostly by influencing the composition of the cerebrospinal
fluid (CSF). Overall, we intend to highlight how the barriers of the
brain, as modulators of regional iron-homeostasis, can influence
AD pathology.
BODY IRON HOMEOSTASIS
Iron is an essential element for cell metabolic processes and tissue
homeostasis, since it is part of enzymes, cytochromes, and protein
prosthetic groups. Although essential, deficiency or excess of iron
can lead to pathological conditions such as anemia or hemochro-
matosis (HFE), respectively; therefore, iron metabolism must
be tightly regulated. The main site of dietary iron absorption
is the duodenum. Once within enterocytes, iron enters a com-
mon intracellular pool and is subsequently transferred across the
basolateral surface into the bloodstream by the well character-
ized mammalian iron exporter ferroportin (FPN) (Graham et al.,
2007). The released ferrous (Fe2+) iron is then oxidized to ferric
(Fe3+) iron by hephaestin, a homolog of the serum ferroxidase
ceruloplasmin, binds to circulating plasma transferrin (TF) and
is subsequently taken up by cells through transferrin receptor 1
(TFR1)-mediated endocytosis (Graham et al., 2007).
The liver, particularly the hepatocyte, is the main site of iron
deposition and storage (Anderson and Frazer, 2005). However,
most of the body iron content exists in circulation inside ery-
throcytes. Within the cells, iron is incorporated into ferritin
(composed by a heavy and a light chain, FTH and FTL). When
the body is iron-replete, macrophages of the liver, spleen, bone
marrow, and reticuloendothelial system can also store iron recov-
ered from the phagocytosis of senescent erythrocytes. Inside the
macrophage, iron is released from hemoglobin and can either
be stored or released back into the circulation (Steele et al.,
2005; Camaschella and Pagani, 2011). Depending on the intra-
cellular iron levels, each cell regulates iron uptake mostly by
modulating the expression of TFR1, while the efflux of iron
through FPN is regulated systemically under the control of the
liver-derived peptide hepcidin (HAMP) (Krause et al., 2000).
Circulating HAMP binds FPN on the surface of enterocytes,
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macrophages, and other cell types causing its internalization and
degradation (Ganz, 2011). Under physiological conditions the
level of HAMP is regulated by body iron requirements via a
complex cell signaling pathway that includes several cell mem-
brane proteins such as HFE, transferrin receptor 2 (TFR2), and
hemojuvelin (HJV) (Schmidt et al., 2008). Of interest, HAMP
expression can also be modulated by proinflammatory cytokines
such as interleukin-1β and -6 (IL-1β and IL-6), which are up-
regulated early during an inflammatory response (Lee et al.,
2005).
Iron metabolism is impaired in several diseases where the level
of specific iron-related proteins, such as HAMP or HFE, is low or
absent. For example, in HFE, a disease characterized bymutations
in the Hfe gene, HAMP production is impaired leading to a wide
generalized iron overload in peripheral organs (Chua et al., 2004;
Schmidt et al., 2008; Ganz and Nemeth, 2011). Interestingly, a
striking observation is that the concentration of iron in the
brain of mice with HFE appears to remain unaltered, despite
the increase in circulating iron (Moos et al., 2000) and severe
iron-overload in hepatocytes (Chua et al., 2004). These observa-
tions support the idea that the barriers of the brain may play an
important role by preventing brain iron-overload (Rouault and
Cooperman, 2006). However, in the context of several diseases
in which iron accumulates in the CNS, such as AD (Duce et al.,
2010), Parkinson’s disease (Lei et al., 2012), or multiple sclerosis
(Williams et al., 2012), the barriers of the brain appear to become
progressively dysfunctional which is likely to impair their ability
to regulate iron exchange between the periphery and the CNS.
In fact, we recently showed that the CP epithelial cells, which
compose the blood-CSF barrier (BCSFB), express all the genes
known to participate in themodulation of iron homeostasis in the
periphery, and therefore, seem well positioned to similarly reg-
ulate brain iron homeostasis (Marques et al., 2009a). However,
little is known on how these may relate to neurodegenerative
disorders.
THE ROLE OF THE CP IN BRAIN IRON METABOLISM
In all mammals, the CP is formed by a monolayer of epithelial
cells that surround and enclose a central stroma. These epithelial
cells are juxtaposed due to the apical localization of tight junc-
tions (Engelhardt and Sorokin, 2009). The adult CP is highly
irrigated by sinusoidal and fenestrated capillaries that are present
in the inner stroma (Johansson et al., 2008; Wolburg and Paulus,
2010). The apical cytoplasmic membrane of the CP epithelial
cells faces the CSF and contains numerous villosities, while the
basolateral side faces the blood in the inner stroma, although
indirectly, by contacting with the fenestrated capillaries (Emerich
et al., 2005). Under physiological conditions, the CP epithelium
forms a barrier that selectively restricts the access of molecules
and blood circulating cells, from the stroma to the CSF and hence
to the brain parenchyma (Engelhardt et al., 2001; Engelhardt and
Sorokin, 2009). The CP is responsible for the secretion of the
major components of the CSF and the transport of nutrients and
trophic factors from the blood into the CSF (Figure 1) (Johanson
et al., 2004). Moreover, the CP is involved in brain detoxification
processes, by clearing several brain metabolites, such as amyloid
beta (Aβ) in the context of AD, from the CSF to the blood stream
(Carro et al., 2005; Vargas et al., 2010; Wolburg and Paulus,
2010).
Importantly, both the BCSFB and the blood-brain barrier
(BBB) were shown to be two major sites of iron exchange between
the periphery and the CNS. It is well-established that iron-loaded
TF and its receptors are in part responsible for most of the
iron content of the CNS. However, there are still some missing
details concerning the mechanisms through which iron reaches
the brain. In the BBB interface, holo-TF present in the circulat-
ing blood reaches the luminal surface of the endothelial cells and
binds TFR1. The TF-receptor complex is internalized and, inside
the endosome, the acidic environment leads to the release of the
two Fe3+ particles from TF, which are thought to be reduced
into Fe2+ by duodenal cytochrome B (DCYTB). The transport
of Fe2+ from the endosomes into the cytosol of the endothe-
lial cells remains controversial, due to absence of divalent metal
transporter-1 (DMT1) expression in these cells (Moos et al.,
2006). Nevertheless, Fe2+ is released into the cytosol and reaches
the abluminal side of the endothelial cell (Moos et al., 2007), to
be excreted out of the cell through FPN. Once in the brain side,
ceruloplasmin, produced in astrocyte end-foot processes, oxidizes
newly released Fe2+ to Fe3+, which again binds to TF (Benarroch,
2009) that is the main source of iron for neurons. Alternatively,
Fe2+ can bind to low-molecular weight constituents, such as
ATP and citrate that are present in the interstitial fluid in high
concentrations and constitute an important source of iron to
oligodendrocytes and astrocytes (Petroff et al., 1986; Montana
et al., 2006). On the other hand, iron can be exported back
into the interstitial fluid from astrocytes, oligodendrocytes, and
neurons through FPN (Wu et al., 2004).
As mentioned, in addition to the endothelial cells, the cells
that compose the BCSFB also play a crucial role in the modula-
tion of regional iron levels, namely by the iron exchange between
the blood and the CSF (Morris et al., 1992; Rouault et al., 2009).
Similarly to endothelial cells, CP epithelial cells express TFR1 in
the basolateral membrane, which binds to TF-bound iron arriv-
ing from the blood stream, inducing its internalization (Morris
et al., 1992). Iron will then reach the cytosol of the epithelial cells
following the TFR1mechanism previously described that involves
the endosomal proteins DMT1 and DCYTB (Figure 2) (Rouault
et al., 2009). Moreover, the presence of FPN in the apical mem-
brane of CP epithelial cells (Figure 2) (Wu et al., 2004) leads to
the release of iron into the CSF, where it circulates bound to
TF. Of notice, CP epithelial cells express other iron-related pro-
teins under physiological conditions, namely HJV, HFE, TFR2,
FTH, FTL, hephaestin, and ceruloplasmin (Figure 2) (Rouault
and Cooperman, 2006; Rouault et al., 2009).
In a mouse model of peripheral inflammation, the CP was
shown to rapidly respond also under adverse conditions, acting
as an immune sensor for the brain (Marques et al., 2007, 2009b).
Surprisingly, as early as one hour after peripheral administra-
tion of bacterial lipopolysaccharide (LPS), the up-regulation of
IL-1β and TNFα gene expression is observed in the CP (Quan
et al., 1998, 1999; Marques et al., 2007). Both proinflammatory
molecules are able to modulate the expression of iron-related
proteins, such as HAMP, whose expression was similarly found
increased (Marques et al., 2009a). Additionally, the analysis of the
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FIGURE 1 | The choroid plexus (CP) epithelial cells’ morphology
and architecture present a progressive decline throughout
the aging process. These features are aggravated in Alzheimer’s
disease (AD) and relate with increased oxidative stress and inflammation
and decrease nutrient transport and secretion into the cerebrospinal
fluid (CSF).
CP’s transcriptome in response to the peripheral LPS injection
revealed that the most up-regulated gene encodes for lipocalin
2 (LCN2), an increase that is similarly reflected in the CSF pro-
tein concentration (Marques et al., 2008). LCN2 is an acute phase
protein initially found in neutrophil granules (Kjeldsen et al.,
1993) and later described as a liver acute phase protein (Liu
and Nilsen-Hamilton, 1995). LCN2 is also an iron-related pro-
tein since it is able to sequester bacterial iron-loaded siderophores
and, therefore, participate in the mammalian innate immune
response by limiting iron availability for bacteria (Sunil et al.,
2007). However, in light of the recent discovery of an endoge-
nous mammalian siderophore (Devireddy et al., 2010), and also
since LCN2 requires catechol to bind and transport iron in the
blood (Bao et al., 2010), it became clear that LCN2 can have an
important physiological role, which is not completely unraveled,
and may include iron uptake and release by cells that express
LCN2 receptors, namely 24p3R. Additionally, other reports have
implicated different roles for LCN2 in various cell types, namely
as a protective protein against oxidative stress (Roudkenar et al.,
2011), as a mitogen (Lee et al., 2009) and as an inducer of apop-
tosis (Devireddy et al., 2005). Despite these findings and the
well-characterized role of LCN2 in neutrophils and in response to
infection, its role in the CNS remains poorly explored. Still, recent
studies have suggested LCN2 participation in processes such as
inflammation, astrogliosis, and cell migration in the brain (Lee
et al., 2009, 2011; Rathore et al., 2011), and also anxious (Mucha
et al., 2011) and cognitive behaviors (Choi et al., 2011).
Altogether, the ability of the CP to rapidly respond to periph-
eral inflammatory stimuli by modulating the expression of iron-
related proteins such as HAMP and LCN2 (Marques et al.,
2009b,c) may be relevant when addressing aging or aging-
associated diseases such as AD, where an increased in the basal
level of peripheral proinflammatory molecules is observed in the
absence of infection (Villeda et al., 2011) and iron seems to play
a crucial role in the development and progression of the disease
(Duce and Bush, 2010).
WHY IRON AND AD?
AD is a neurodegenerative disease characterized by two main
brain pathological hallmarks: the formation of extracellular senile
plaques, resulting from Aβ peptide deposition, and the presence
of neurofibrillary tangles composed by intracellular hyperphos-
phorylated tau. It is thought that much of the early pathological
events in AD are due to the formation of dimeric and oligomeric
forms of Aβ, which are formed through site-specific cleavage
of APP (Walsh et al., 2005; Walsh and Selkoe, 2007) and accu-
mulate in the brain. Importantly, Aβ accumulation may result
from decreased clearance of the Aβ peptides through the barri-
ers of the brain (Serot et al., 2003; Zlokovic, 2004; Crossgrove
et al., 2005). Although the mechanisms that elicit the formation
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FIGURE 2 | The CP epithelial cells may participate in the regional
regulation of brain iron metabolism due to the presence of specific
membrane and secreted proteins. These epithelial cells express
receptors that are directly or indirectly involved in iron uptake, such as
transferrin receptors type 1 and 2 (TFR1 and 2) (1) as well as
hemochromatosis (HFE) protein that is able to bind to TFR2; (2) Duodenal
cytochrome B (DCYTB) and divalent metal transporter 1 (DMT1) are present
in the basolateral membrane and, respectively, reduce ferric iron (Fe3+) to
ferrous iron (Fe2+ ) and transport it into the cell; (3) An iron exporter localized
in the apical face of the CP epithelial cell, ferroportin (FPN), can be
internalized and degraded through the action of hepcidin (HAMP); (4) a
hormone also produced by the CP in response to specific conditions, such as
an inflammatory stimulus, through STAT3 and SMAD4 transcription factors.
While the activation of STAT3 is likely to occur through IL-6, SMAD4 activation
is probably mediated through the complex hemojuvelin (HJV)-bone
morphogenetic protein (BMP)/SMAD4; (5) HAMP may then be secreted
into the CSF and bind, in the apical side, to FPN and induce its internalization
and degradation, therefore, preventing iron release into the CSF; (6) Heme
oxygenase 1 (HO-1), which is expressed by the CP, is an inducible
oxygenase that has the ability to recycle heme, originating free Fe2+;
(7) Additionally, the CP epithelial cells can also produce important peptides
that are directly or indirectly involved in iron transport, oxidation, and storage,
such as lipocalin 2 (LCN2), transferrin (TF), ceruloplasmin, ferritin, and
hephaestin; (8) In the context of aging and AD, other important molecules,
which are also expressed in the CP, have recently been shown to be
involved in iron homeostasis, like PACE/furin and amyloid precursor protein
(APP); (9) Overall, changes in the expression of iron-related genes at the
blood-CSF barrier may interfere with the level of iron in the brain and
consequently trigger and/or aggravate aging and AD-related pathological
events.
of these toxic soluble agglomerates and, later on, insoluble fibrils
and senile plaques are still poorly understood (Walsh and Selkoe,
2007; Querfurth and LaFerla, 2010), it is thought that free divalent
metals such as iron, which give rise to strong oxidative radicals,
maybe closely involved (Duce et al., 2010; Leskovjan et al., 2011;
Liu et al., 2011).
Several observations in various cellular and animal models
link iron and AD. For instance, APP, whose physiological func-
tion is still uncertain, was recently suggested to be up-regulated
by iron and to favor the presence of iron deposits in amyloid
plaques (Gaeta and Hider, 2005; Cahill et al., 2009). Indeed, an
iron-responsive element (IRE) exists within the 5’-untranslated
region of the APP transcript and this IRE allows iron to regulate
the intracellular APP level the same way it regulates the tran-
scription of genes that encode for FTH and FTL (Rogers et al.,
2002). Additionally, the APP-IRE is also located up-stream of an
IL-1 responsive domain (Rogers et al., 1999), which means that
a proinflammatory stimulus may trigger APP gene expression.
Importantly, APP was shown to have an iron-export ferroxidase
activity (Duce et al., 2010). As a ferroxidase, APP participates
in the export of iron from the cells, by mediating the oxidation
of Fe2+ into Fe3+ (Duce et al., 2010). APP shares similarities
with other ferroxidases, such as FTH and ceruloplasmin, being
its activity inhibited by zinc and not by copper, a resembling fea-
ture of FTH but not of ceruloplasmin. However, APP is similar
to ceruloplasmin since it interacts with FPN in order to export
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iron out of cells, a fact that was shown in a study using human
embryonic kidney 293T cells that do not express ceruloplasmin
(Duce et al., 2010). Moreover, in vivo experiments have shown
that APP-nullmice fed with an iron-rich diet have decreased Fe2+
efflux and increased iron accumulation inside brain cells, as well
as a higher percentage of protein carbonylation and lower level of
glutathione in the brain and liver (Duce et al., 2010).
Another interesting observation is that PACE, which is respon-
sible for the activation of β-secretase involved in the amyloido-
genic pathway, is positively modulated by iron uptake. High
cellular iron content indirectly favors the formation of amyloido-
genic peptides in AD, through the activation of PACE (Silvestri
and Camaschella, 2008). Moreover, one of the products of the
enzymatic action of PACE is soluble hemojuvelin (sHJV) (Silvestri
et al., 2008), which was shown to compete with membrane HJV
(mHJV) for bone morphogenetic protein (BMP) signaling. Since
BMP signaling can lead to the up-regulation of Hamp (Babitt
et al., 2006), namely in CP epithelial cells (Figure 2) (Marques
et al., 2009a), the activity of PACE may indirectly modulate the
expression of Hamp in the brain.
The influence of excessive brain iron on the toxicity of Aβ pep-
tides and fibrils in AD is, in part, explained by the effect of this
metal on the formation of oxidative hydroxyl radicals (Rival et al.,
2009). By increasing the levels of the intracellular iron binding
protein, ferritin, it was possible to rescue the phenotype asso-
ciated with deposition of Aβ in a Drosophila fly model (Rival
et al., 2009), which was correlated with a decreased level of protein
carbonylation. Recently, iron was also linked to the aggregation
process of Aβ (Liu et al., 2011). The presence of Fe3+ during the
aggregation process of Aβ monomers into fibrils was shown to
impede, later on, the fusion of fibrils into the less toxic amyloid
deposits and to favor the stabilization of more toxic intermediate
forms of Aβ. Toxic Aβ intermediates originated by Fe3+ do not
interact with thioflavin T and their final structure is less ordered,
which delays the formation of senile plaques. Importantly, the for-
mation of fibrils in the presence of iron was shown to lead to
increased apoptosis in a neuronal cell line (Liu et al., 2011). In
accordance, metal chelation with clioquinol (that sequesters iron,
copper, and zinc) was shown to increase the lifespan of flies over-
expressing Aβ1−42 (Rival et al., 2009), to improve the cognitive
performance and to reduce brain amyloid load in a mouse model
of AD (Grossi et al., 2009).
THE SENESCENT CP: IMPLICATIONS IN AGING AND IN AD
The senescence of the CP is a gradual aging process. Aged CP
epithelial cells present a general atrophy when compared to the
adult CP (Figure 1). The epithelial cells display a decrease in
height, total volume (Serot et al., 2000) and length of the api-
cal microvilli (Serot et al., 2003). A striking deterioration of the
CP epithelial cells is observed in AD (Wen et al., 1999; Johanson
et al., 2004); the basement membrane, stroma, and blood vessel
walls of the CP become thicker with age and acquire an irreg-
ular form in AD (Serot et al., 2000; Preston, 2001; Johanson
et al., 2004). The accumulation of Aβ1−40 and Aβ1−42 peptides
in CP epithelial cells (Figure 1) is, to a great extent, responsible
for an increased level of oxidative stress and cell death (Vargas
et al., 2010). Additionally, the extracellular deposition of Aβ in
the apical membrane, near the tight junctions, further enhances
the disruption of the BCSFB (Figure 1) (Marco and Skaper, 2006;
Vargas et al., 2010). The barrier properties of the CP progressively
decay, which becomes leakier (Chalbot et al., 2011). In addition,
its ability to secrete Aβ-carrier proteins and to express impor-
tant receptors that scavenge amyloidogenic peptides was shown to
decrease with age and to be compromised in several models of AD
(Figures 1 and 3) (Zlokovic et al., 1996; Crossgrove et al., 2005;
Antequera et al., 2009). A decreased activity of enzymes involved
in oxidative phosphorylation (Preston, 2001) and mitochondrial
respiratory chain, such as cytochrome C oxidase (Emerich et al.,
2005), may also contribute to the impaired protein synthesis in
the CP. This decrease in the metabolic activity of CP epithelial
cells is in part correlated with Aβ-induced mitochondrial dys-
function (Figure 1) (Cornford et al., 1997; Vargas et al., 2010).
These harmful events that damage the CP’s morphology and
architecture (Figure 1), together with a massive and extensive
fibrosis observed in the central stroma and the surroundings of
the CP, are also responsible for the deficits in molecular exchanges
between the CP and the CSF (Johanson et al., 2004). Moreover,
the CP’s capacity to promote the flow and the renewal of the CSF
also declines with age and in AD (Preston, 2001; Redzic et al.,
2005; Johanson et al., 2008).
The decrease in protein secretion and renewal of the CSF may
be involved in the initiation and progression of AD. As men-
tioned, some CP proteins are known to interact with Aβ and
this could be in the basis of Aβ clearance. One of such proteins
is transthyretin (TTR), which is the major protein synthesized
and secreted by the CP into the CSF (Dickson et al., 1986) and
has been shown to bind and stabilize soluble Aβ (Li et al., 2000;
Tang et al., 2004) (Figure 3). Of interest, the absence of TTR
in the mouse has been shown to accelerate the aging-associated
cognitive decline (Sousa et al., 2007) and is associated with anx-
ious behavior (Sousa et al., 2004). Additionally, transgenic mice
that overexpress mutated forms of human APP and presenilin
1, and comprise hemizigous deletions for the TTR gene, present
an accelerated deposition of Aβ in the hippocampus and cortex
(Doggui et al., 2010) and increased Aβ-toxicity in the hippocam-
pus when compared to control mice (Choi et al., 2007). These
features appear to be directly involved with the decreased level
of TTR in the brain. Moreover, decreased level of TTR in the
CSF has been reported in patients with severe dementia and in
AD (Riisoen, 1988; Serot et al., 1997), but some controversy sub-
sists regarding the levels and functions of TTR in the brain and in
cognition (Wati et al., 2009).
Other two important proteins produced and secreted by the
CP are insulin growth factors 1 and 2 (IGF-1 and -2). Both are
relevant in the context of AD (Preston, 2001; Emerich et al.,
2005) since they seem to modulate the clearance of Aβ from the
AD brain (Figure 3). Importantly, the presence of IGF-1 in the
CSF stimulates CP epithelial cells to express megalin/LRP-2 and
to secrete Aβ-binding proteins that are recognized by megalin,
namely TTR and clusterin, which favor the transport of these
Aβ complexes from the brain into the blood (Figure 3) (Carro
et al., 2002; Carro and Torres-Aleman, 2004). Shutting down the
IGF-1 receptor signaling pathway in the CP was shown to exacer-
bate AD brain pathology in a mouse model (Carro et al., 2006)
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FIGURE 3 | A strong interaction is observed between the different cells
that compose the blood-CSF barrier and the cells from the brain
parenchyma. In the context of aging and AD, the development and
progression of the disease strongly depends on the formation of different
size amyloid beta (Aβ) oligomers that deposit in the brain and are highly toxic.
In order to prevent this, the CP epithelial cells secrete peptides to the CSF,
which have the ability to bind, sequester, and remove Aβ peptides, from
the brain and CSF into the blood stream, through specific receptors
present in the apical membrane (AAT, alpha 1 antitrypsin; APO-J,
apolipoprotein-J/clusterin; IGF-1/2, insulin-like growth factor 1/2; P-gp,
P-glycoprotein; PTGDS, prostaglandin D2 synthase; LRP-1/2, low density
lipoprotein receptor-related protein-1/2; TTR, transthyretin).
and silencing the expression of insulin and insulin-like growth
factors in the brain was linked to increased levels of APP, glio-
sis, and lower level of acetylcholine (Carro et al., 2002; Rivera
et al., 2005). Interestingly, two studies performed with samples
from AD patients point to increased levels of IGF-1 (Salehi et al.,
2008) and IGF-2 (Tham et al., 1993) in the serum and CSF, which
indicate that controversy still remains.
Whilst these observations implicate dysfunction of the BCSFB
regarding the modulation of Aβ sequestration and clearance in
aging and in AD, available data also suggest a role of the barriers in
iron deregulation and oxidative stress, as it will next be addressed.
IS THE AGED BLOOD-CSF BARRIER CONTRIBUTING
FOR IRON DEREGULATIONWITHIN THE BRAIN?
In models of aging and AD, the CP was shown to contribute for
the increase in reactive oxygen and nitrogen species observed in
the brain. This increase in oxidative stress may, to some extent,
be connected to an increased iron concentration, which in itself
may lead to the formation of reactive species through the Fenton’s
reaction (Kell, 2009). However, a central question remains to be
answered in the AD brain: whether CP epithelial cells accumulate
iron in excess, as an attempt to protect the brain parenchyma,
or present some sort of deficit regarding the transport of iron
out of the brain. A hypothetical increase in intracellular iron
in CP epithelial cells may prevent the correct functioning of
enzymes involved in the mitochondrial respiratory chain, which
could be one of the causes for increased mitochondrial stress
and cell apoptosis, shown to occur in the CP from patients with
AD (Vargas et al., 2010). Moreover, in AD, besides the forma-
tion of reactive species and protein carbonylation, traditional
markers of oxidative stress are up-regulated in CP epithelial cells,
namely heat shock protein-90 and heme oxygenase-1 (HO-1)
(Anthony et al., 2003). HO-1 in particular is directly involved
in iron-metabolism, since it recycles heme, therefore, releasing
free iron and contributing to increased levels of intracellular iron
(Figure 2). Surprisingly, a high expression of APP was shown to
inhibit HO-1 and HO-2 activity and to accentuate free heme and
possibly free iron neuronal toxicity (Takahashi et al., 2000).
Besides oxidative stress, inflammation is another process that is
closely associated with the brain iron levels. As mentioned before,
it has been recently suggested that increased levels of peripheral
inflammation can induce a response in the CP and influence
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iron-metabolism (Marques et al., 2007, 2009a,b). As early as 3 h
after peripheral LPS administration, the expression of Il-6 and
Hamp is significantly up-regulated in the mouse CP (Figure 2)
(Marques et al., 2009a). Taking this feature of the CP epithelial
cells into account, it is plausible that the CP is functioning in
the brain as a regulator of iron-metabolism when an inflamma-
tory environment is established. It would be of great interest to
know if that is the case in aging and in AD, since it is recognized
that the levels of proinflammatory cytokines in the blood increase
with age (Villeda et al., 2011), which can influence the secre-
tion of iron-metabolism-related proteins, such as HAMP, by CP
epithelial cells. A recent study has shown that increased peripheral
markers of inflammation, measured in the blood of aged subjects,
do not correlate with increased levels of blood circulating HAMP
or low iron status in the brain (Ferrucci et al., 2010); however,
nothing is known concerning the levels of HAMP in the brain
cells or CSF of aged individuals. On the other hand, IL-6, that is
able to trigger the cell’s STAT3 signaling pathway, appears to be
associated to old-age anemia and is over-expressed in the aged
mouse brain in response to LPS (Chen et al., 2008). Since IL-6
was shown to participate in the regulation of the expression of
Hamp, not only in the liver (Lee et al., 2005) but also in the CP
(Marques et al., 2009a) of adult mice, it remains to be assessed if
the CP contributes to the level of IL-6 in the aged brain (Figure 2).
Moreover, the CP is able to up-regulate genes that encode for
iron-related proteins and transcription factors, such as Tfr2, Fth,
Cp (ceruloplasmin), Stat3, and Smad4 (Figure 2), in conditions
of peripheral inflammation, and these may contribute to regional
regulation of iron in the CNS (Marques et al., 2009a). In aging
and in AD, however, the pattern of expression of these genes by
the CP is still unknown.
Altogether, the aging process is accompanied by increasing lev-
els of inflammation and oxidative stress, both in the periphery
and in the brain, which can elicit changes in the CP’s capacity
to regulate iron metabolism and to impact on the initiation and
progression of brain pathology in AD.
CONCLUDING REMARKS
The CP, as a secretory tissue, influences the composition of the
CSF and, therefore, the brain milieu. Brain faculties progressively
decline with aging and are severely affected in AD. Age-dependent
alterations at the level of the BCSFB may impact on the patholog-
ical events that take place in the AD brain. Additionally, recent
studies strongly suggest that alterations in iron metabolism and
iron-related proteins can impact on initiation and progression of
AD pathology. Since the barriers of the brain can act as impor-
tant regulators of iron metabolism, it is timely to investigate
how they impact on brain homeostasis in aging and in AD. The
senescent-aged/AD CP epithelial cells may present alterations in
the expression of iron-carrier proteins and their receptors, such as
LCN2 and 24p3R or TF and TFR1, or in proteins involved in iron
export and storage, like HAMP, FPN, and FTH (Figure 2) that
will strongly influence iron homeostasis in the mammalian brain.
A dysregulation of the level of iron in the brain will enhance the
amyloidogenic pathway and potentiate the aggregation and toxic-
ity of Aβwhich, together with a decreased excretion of Aβ through
the CSF/CP/BBB (Figure 3) may impact on the progression of
brain pathology in AD.We believe that themodulation of the CP’s
function in this context can be a new potential therapeutic target
to prevent or delay the rapid aging and decay of the brain in AD.
Importantly, progressive aging-related changes in the transcrip-
tome and secretome of CP epithelial cells may be associated with
the diagnosis and prognosis of AD, andmay eventually lead to the
discovery of reliable markers of AD initiation and progression.
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